Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 30;15(17):4336.
doi: 10.3390/cancers15174336.

Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer-A Literature Review

Danilo Giffoni de Mello Morais Mata  1 , Rania Chehade  2 , Malek B Hannouf  3 , Jacques Raphael  1 , Phillip Blanchette  1 , Abdullah Al-Humiqani  2 , Monali Ray  4
Affiliations
Review

Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer-A Literature Review

Danilo Giffoni de Mello Morais Mata et al. Cancers (Basel). .

Abstract

Background: The overexpression of the human epidermal growth factor receptor 2 (HER2+) accounts for 15-20% of all breast cancer phenotypes. Even after the completion of the standard combination of chemotherapy and trastuzumab, relapse events occur in approximately 15% of cases. The neoadjuvant approach has multiple benefits that include the potential to downgrade staging and convert previously unresectable tumors to operable tumors. In addition, achieving a pathologic complete response (pCR) following preoperative systemic treatment is prognostic of enhanced survival outcomes. Thus, optimal evaluation among the suitable strategies is crucial in deciding which patients should be selected for the neoadjuvant approach.

Methods: A literature search was conducted in the Embase, Medline, and Cochrane electronic libraries.

Conclusion: The evaluation of tumor and LN staging and, hence, stratifying BC recurrence risk are decisive factors in guiding clinicians to optimize treatment decisions between the neoadjuvant versus adjuvant approaches. For each individual case, it is important to consider the most likely postsurgical outcome, since, if the patient does not obtain pCR following neoadjuvant treatment, they are eligible for adjuvant T-DM1 in the case of residual disease. This review of HER2-positive female BC outlines suitable neoadjuvant and adjuvant systemic treatment strategies for guiding clinical decision making around the selection of an appropriate therapy.

Keywords: chemotherapy; human epidermal growth factor receptor 2-positive; invasive breast carcinoma; monoclonal antibody; neoadjuvant and adjuvant treatment; pertuzumab; trastuzumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Timeline of the FDA-approved targeted treatments against the HER domains. mAB: monoclonal antibody, TKI: tyrosine kinase inhibitor, ADC: antibody drug conjugate, SC: sub-cutaneous.
Figure 2
Figure 2
Flowchart of Systemic Therapy Strategies in Early HER2-Positive Breast Cancer.
See this image and copyright information in PMC

References

    1. Mayer E.L., Fesl C., Hlauschek D., Garcia-Estevez L., Burstein H.J., Zdenkowski N., Wette V., Miller K.D., Balic M., Mayer I.A., et al. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib with Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03) J. Clin. Oncol. 2022;40:449–458. doi: 10.1200/JCO.21.01918. - DOI - PMC - PubMed
    1. Alferez D.G., Simões B.M., Howell S.J., Clarke R.B. The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells. Curr. Stem Cell Rep. 2018;4:81–94. doi: 10.1007/s40778-018-0114-z. - DOI - PMC - PubMed
    1. Loibl S., Gianni L. HER2-positive breast cancer. Lancet. 2017;389:2415–2429. doi: 10.1016/S0140-6736(16)32417-5. - DOI - PubMed
    1. Patel A., Unni N., Peng Y. The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. Cancers. 2020;12:2081. doi: 10.3390/cancers12082081. - DOI - PMC - PubMed
    1. Mata D.G.D.M.M., Carmona A., Eisen C., Trudeau A., Giffoni D., Morais Mata M., Carmona C.A., Eisen A., Trudeau M. Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review. Curr. Oncol. 2022;29:4956–4969. doi: 10.3390/curroncol29070394. - DOI - PMC - PubMed

LinkOut - more resources